Literature DB >> 30427997

Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.

Daniel Lindholm1,2, Stefan K James1,2, Katja Gabrysch2, Robert F Storey3, Anders Himmelmann4, Christopher P Cannon5,6, Kenneth W Mahaffey7, Philippe Gabriel Steg8,9,10, Claes Held1,2, Agneta Siegbahn2,11, Lars Wallentin1,2.   

Abstract

Importance: Mortality remains at about 5% within a year after an acute coronary syndrome event. Prior studies have assessed biomarkers in relation to all-cause or cardiovascular deaths but not across multiple causes. Objective: To assess if different biomarkers provide information about the risk for all-cause and cause-specific mortality. Design, Setting, and Participants: The Platelet Inhibition and Patient Outcomes (PLATO) trial randomized 18 624 patients with acute coronary syndrome to ticagrelor or clopidogrel from October 2006 through July 2008. In this secondary analysis biomarker substudy, 17 095 patients participated. Main Outcomes and Measures: Death due to myocardial infarction, heart failure, sudden cardiac death/arrhythmia, bleeding, procedures, other vascular causes, and nonvascular causes, as well as all-cause death. Exposures: At baseline, levels of cystatin-C, growth differentiation factor-15 (GDF-15), high-sensitivity C-reactive protein, high-sensitivity troponin I and T, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were determined.
Results: The median (interquartile range) age of patients was 62.0 (54.0-71.0) years. Of 17 095 patients, 782 (4.6%) died during follow-up. The continuous associations between biomarkers and all-cause and cause-specific mortality were modeled using Cox models and presented as hazard ratio (HR) comparing the upper vs lower quartile. For all-cause mortality, NT-proBNP and GDF-15 were the strongest markers with adjusted HRs of 2.96 (95% CI, 2.33-3.76) and 2.65 (95% CI, 2.17-3.24), respectively. Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk. Regarding sudden cardiac death/arrhythmia, NT-proBNP was associated with a 4-fold increased risk and GDF-15 with a doubling in risk. Growth differentiation factor-15 had the strongest associations with other vascular and nonvascular deaths and was possibly associated with death due to major bleeding (HR, 4.91; 95% CI, 1.39-17.43). Conclusions and Relevance: In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death. Growth differentiation factor-15 had the strongest associations with death due to other vascular or nonvascular causes and possibly with death due to bleeding. Trial Registration: ClinicalTrials.gov Identifier: NCT00391872.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30427997      PMCID: PMC6583102          DOI: 10.1001/jamacardio.2018.3811

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  33 in total

1.  Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.

Authors:  Christoph Varenhorst; Ulrica Alström; Oscar Ö Braun; Robert F Storey; Kenneth W Mahaffey; Maria Bertilsson; Christopher P Cannon; Benjamin M Scirica; Anders Himmelmann; Stefan K James; Lars Wallentin; Claes Held
Journal:  Heart       Date:  2014-06-23       Impact factor: 5.994

2.  The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.

Authors:  Ziad Hijazi; Jonas Oldgren; Johan Lindbäck; John H Alexander; Stuart J Connolly; John W Eikelboom; Michael D Ezekowitz; Claes Held; Elaine M Hylek; Renato D Lopes; Agneta Siegbahn; Salim Yusuf; Christopher B Granger; Lars Wallentin
Journal:  Lancet       Date:  2016-04-04       Impact factor: 79.321

3.  The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL.

Authors:  Paul J Emmerson; Feng Wang; Yong Du; Qian Liu; Richard T Pickard; Malgorzata D Gonciarz; Tamer Coskun; Matthew J Hamang; Dana K Sindelar; Kimberly K Ballman; Lisa A Foltz; Avinash Muppidi; Jorge Alsina-Fernandez; Gavin C Barnard; Jason X Tang; Xilin Liu; Xudong Mao; Robert Siegel; John H Sloan; Pamela J Mitchell; Bei B Zhang; Ruth E Gimeno; Bei Shan; Xinle Wu
Journal:  Nat Med       Date:  2017-08-28       Impact factor: 53.440

4.  Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction.

Authors:  E Björklund; T Jernberg; P Johanson; P Venge; M Dellborg; L Wallentin; B Lindahl
Journal:  Heart       Date:  2005-10-26       Impact factor: 5.994

5.  GDF-15 prevents platelet integrin activation and thrombus formation.

Authors:  J Rossaint; D Vestweber; A Zarbock
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

6.  Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.

Authors:  Emil Hagström; Claes Held; Ralph A H Stewart; Philip E Aylward; Andrzej Budaj; Christopher P Cannon; Wolfgang Koenig; Sue Krug-Gourley; Emile R Mohler; Philippe Gabriel Steg; Elizabeth Tarka; Ollie Östlund; Harvey D White; Agneta Siegbahn; Lars Wallentin
Journal:  Clin Chem       Date:  2016-11-03       Impact factor: 8.327

7.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

Authors:  J A de Lemos; D A Morrow; J H Bentley; T Omland; M S Sabatine; C H McCabe; C Hall; C P Cannon; E Braunwald
Journal:  N Engl J Med       Date:  2001-10-04       Impact factor: 91.245

8.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

9.  Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.

Authors:  Daniel Lindholm; Stefan K James; Maria Bertilsson; Richard C Becker; Christopher P Cannon; Evangelos Giannitsis; Robert A Harrington; Anders Himmelmann; Frederic Kontny; Agneta Siegbahn; Philippe Gabriel Steg; Robert F Storey; Matthijs A Velders; W Douglas Weaver; Lars Wallentin
Journal:  Clin Chem       Date:  2016-12-08       Impact factor: 8.327

10.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  2013-11-27       Impact factor: 56.272

View more
  21 in total

1.  Putting the Measurement of Physical Capacity of Older Adults in Its Place.

Authors:  Stephen B Kritchevsky
Journal:  Circulation       Date:  2019-04-23       Impact factor: 29.690

Review 2.  GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease.

Authors:  Dongdong Wang; Emily A Day; Logan K Townsend; Djordje Djordjevic; Sebastian Beck Jørgensen; Gregory R Steinberg
Journal:  Nat Rev Endocrinol       Date:  2021-08-11       Impact factor: 43.330

3.  Evaluation of Growth Differentiation Factor-15 in Patients with or without Coronary Artery Disease.

Authors:  Shima Hassanzadeh Daloee; Nima Nakhaei; Mahdy Hassanzadeh Daloee; Mahmood Mahmoodi; Maral Barzegar-Amini
Journal:  Acta Biomed       Date:  2021-05-12

4.  The role of age-specific N-terminal pro-brain natriuretic peptide cutoff values in predicting intravenous immunoglobulin resistance in Kawasaki disease: a prospective cohort study.

Authors:  Shuran Shao; Chunyan Luo; Kaiyu Zhou; Yimin Hua; Mei Wu; Lei Liu; Xiaoliang Liu; Chuan Wang
Journal:  Pediatr Rheumatol Online J       Date:  2019-09-18       Impact factor: 3.054

5.  Editorial: Novel and potential markers for prediction of outcome in patients with acute and chronic coronary heart disease.

Authors:  Hugo Ten Cate; Frederic Kontny; Dennis W Nilsen
Journal:  Front Cardiovasc Med       Date:  2019-05-22

Review 6.  Roles of Growth Differentiation Factor 15 in Atherosclerosis and Coronary Artery Disease.

Authors:  Juan Wang; Liqun Wei; Xinchun Yang; Jiuchang Zhong
Journal:  J Am Heart Assoc       Date:  2019-08-21       Impact factor: 5.501

7.  Longitudinal Growth Differentiation Factor 15 (GDF15) and Long-term Intraocular Pressure Fluctuation in Glaucoma: A Pilot Study.

Authors:  Jonathan B Lin; Arsham Sheybani; Andrea Santeford; Rajendra S Apte
Journal:  J Ophthalmic Vis Res       Date:  2021-01-20

8.  Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease.

Authors:  Man Li; Lei Duan; Yu-Lun Cai; Hui-Ying Li; Ben-Chuan Hao; Jian-Qiao Chen; Hong-Bin Liu
Journal:  Cardiovasc Diabetol       Date:  2020-08-03       Impact factor: 9.951

9.  Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial.

Authors:  Ida Gregersen; Annika E Michelsen; Ngoc Nguyen Lunde; Axel Åkerblom; Tatevik G Lakic; Mona Skjelland; Karolina Ryeng Skagen; Richard C Becker; Johan Lindbäck; Anders Himmelmann; Rigmor Solberg; Harald T Johansen; Stefan K James; Agneta Siegbahn; Robert F Storey; Frederic Kontny; Pål Aukrust; Thor Ueland; Lars Wallentin; Bente Halvorsen
Journal:  J Am Heart Assoc       Date:  2020-08-15       Impact factor: 5.501

10.  Plasma proteomic biomarker signature of age predicts health and life span.

Authors:  Toshiko Tanaka; Nathan Basisty; Giovanna Fantoni; Julián Candia; Ann Z Moore; Angelique Biancotto; Birgit Schilling; Stefania Bandinelli; Luigi Ferrucci
Journal:  Elife       Date:  2020-11-19       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.